112 related articles for article (PubMed ID: 12679396)
1. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
2. (18)F-alfatide II and (18)F-FDG dual-tracer dynamic PET for parametric, early prediction of tumor response to therapy.
Guo J; Guo N; Lang L; Kiesewetter DO; Xie Q; Li Q; Eden HS; Niu G; Chen X
J Nucl Med; 2014 Jan; 55(1):154-60. PubMed ID: 24232871
[TBL] [Abstract][Full Text] [Related]
3. Total-Body Multiparametric PET Quantification of
Wang Y; Nardo L; Spencer BA; Abdelhafez YG; Li EJ; Omidvari N; Chaudhari AJ; Badawi RD; Jones T; Cherry SR; Wang G
J Nucl Med; 2023 Nov; 64(11):1821-1830. PubMed ID: 37591539
[TBL] [Abstract][Full Text] [Related]
4. Multicenter Reproducibility of 18F-Fluciclatide PET Imaging in Subjects with Solid Tumors.
Sharma R; Kallur KG; Ryu JS; Parameswaran RV; Lindman H; Avril N; Gleeson FV; Lee JD; Lee KH; O'Doherty MJ; Groves AM; Miller MP; Somer EJ; Coombes CR; Aboagye EO
J Nucl Med; 2015 Dec; 56(12):1855-61. PubMed ID: 26383153
[TBL] [Abstract][Full Text] [Related]
5. Total-Body Multiparametric PET Quantification of
Wang Y; Nardo L; Spencer BA; Abdelhafez YG; Li EJ; Omidvari N; Chaudhari AJ; Badawi RD; Jones T; Cherry SR; Wang G
medRxiv; 2023 Mar; ():. PubMed ID: 37034643
[TBL] [Abstract][Full Text] [Related]
6.
Husby T; Johannessen K; Berntsen EM; Johansen H; Giskeødegård GF; Karlberg A; Fagerli UM; Eikenes L
EJNMMI Rep; 2024 Jan; 8(1):2. PubMed ID: 38748286
[TBL] [Abstract][Full Text] [Related]
7. Optimization of FDG-PET/CT imaging protocol for evaluation of patients with primary and metastatic liver disease.
Kuker RA; Mesoloras G; Gulec SA
Int Semin Surg Oncol; 2007 Jul; 4():17. PubMed ID: 17623095
[TBL] [Abstract][Full Text] [Related]
8. FDG Dose Extravasations in PET/CT: Frequency and Impact on SUV Measurements.
Osman MM; Muzaffar R; Altinyay ME; Teymouri C
Front Oncol; 2011; 1():41. PubMed ID: 22655246
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of bone remodeling with (18)F-fluoride and correlation with the glucose metabolism measured by (18)F-FDG in lumbar spine with time in an experimental nude rat model with osteoporosis using dynamic PET-CT.
Cheng C; Heiss C; Dimitrakopoulou-Strauss A; Govindarajan P; Schlewitz G; Pan L; Schnettler R; Weber K; Strauss LG
Am J Nucl Med Mol Imaging; 2013; 3(2):118-28. PubMed ID: 23526138
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Immuno-PET of CD138 and PET imaging with
Bailly C; Gouard S; Lacombe M; Remaud-Le Saëc P; Chalopin B; Bourgeois M; Chouin N; Tripier R; Halime Z; Haddad F; Faivre-Chauvet A; Kraeber-Bodéré F; Chérel M; Bodet-Milin C
Oncotarget; 2018 Feb; 9(10):9061-9072. PubMed ID: 29507674
[TBL] [Abstract][Full Text] [Related]
11. Not everything that shines is gold, normal uptake in crista terminalis on FDG PET/CT masquerading as a tumor thrombus approaching right heart.
Ghesani A; Cangut B; Stempler L
Radiol Case Rep; 2024 Feb; 19(2):513-518. PubMed ID: 38044900
[TBL] [Abstract][Full Text] [Related]
12. Fluorine-18 fluorodeoxyglucose uptake change in liver, mediastinal blood pool, and lymphoid cell-rich organs during programmed cell death-1 immunotherapy in lymphoma.
Guo L; Wang R; Shen G
Nucl Med Commun; 2024 May; ():. PubMed ID: 38726632
[TBL] [Abstract][Full Text] [Related]
13. Impact of Renal Failure on F18-FDG PET/CT Scans.
Kode V; Karsch H; Osman MM; Muzaffar R
Front Oncol; 2017; 7():155. PubMed ID: 28785537
[TBL] [Abstract][Full Text] [Related]
14. Computational modeling of PET tracer distribution in solid tumors integrating microvasculature.
Fasaeiyan N; Soltani M; Moradi Kashkooli F; Taatizadeh E; Rahmim A
BMC Biotechnol; 2021 Nov; 21(1):67. PubMed ID: 34823506
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of ¹¹C-methionine PET/CT in patients with plasma cell malignancy: comparison with ¹⁸F-FDG PET/CT.
Nakamoto Y; Kurihara K; Nishizawa M; Yamashita K; Nakatani K; Kondo T; Takaori-Kondo A; Togashi K
Eur J Nucl Med Mol Imaging; 2013 May; 40(5):708-15. PubMed ID: 23340595
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of no-carrier-added 2-[18F]fluoro-L-tyrosine in rats.
Aerts JJ; Plenevaux AR; Lemaire CF; Giacomelli F; Warnock GI; Phillips CL; Luxen AJ
BMC Med Phys; 2008 Nov; 8():4. PubMed ID: 18990255
[TBL] [Abstract][Full Text] [Related]
17. Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography.
Ozaki Y; Oguchi K; Hamano H; Arakura N; Muraki T; Kiyosawa K; Momose M; Kadoya M; Miyata K; Aizawa T; Kawa S
J Gastroenterol; 2008; 43(2):144-51. PubMed ID: 18306988
[TBL] [Abstract][Full Text] [Related]
18. 123/125I-labelled 2-iodo-L: -phenylalanine and 2-iodo-D: -phenylalanine: comparative uptake in various tumour types and biodistribution in mice.
Kersemans V; Cornelissen B; Kersemans K; Bauwens M; Dierckx RA; De Spiegeleer B; Mertens J; Slegers G
Eur J Nucl Med Mol Imaging; 2006 Aug; 33(8):919-27. PubMed ID: 16572305
[TBL] [Abstract][Full Text] [Related]
19. Fluorinated tracers for imaging cancer with positron emission tomography.
Couturier O; Luxen A; Chatal JF; Vuillez JP; Rigo P; Hustinx R
Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1182-206. PubMed ID: 15241631
[TBL] [Abstract][Full Text] [Related]
20. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma.
Naumann R; Beuthien-Baumann B; Reiss A; Schulze J; Hänel A; Bredow J; Kühnel G; Kropp J; Hänel M; Laniado M; Kotzerke J; Ehninger G
Br J Cancer; 2004 Feb; 90(3):620-5. PubMed ID: 14760374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
